See every side of every news story
Published loading...Updated

Rybelsus found to reduce major adverse cardiovascular events in Novo Nordisk trial - Pharmafile

Summary by pharmafile.com
Novo Nordisk announced results from its SOUL cardiovascular outcomes trial. Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD). The new phase 3b data was presented at the American College of Cardiology’s (ACC) Annual Scientific Session […] The post Rybelsus found to reduce major adverse cardiov…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmafile.com broke the news in on Tuesday, April 1, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.